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Abstract
Although liver transplantation is a widely accepted treatment for hepatocellular carcinoma (HCC),
much controversy remains and there is no generally accepted set of guidelines. An international
consensus conference was held on Dec 2–4, 2010, in Zurich, Switzerland, with the aim of
reviewing current practice regarding liver transplantation in patients with HCC and to develop
internationally accepted statements and guidelines. The format of the conference was based on the
Danish model. 19 working groups of experts prepared evidence-based reviews according to the
Oxford classification, and drafted recommendations answering 19 specific questions. An
independent jury of nine members was appointed to review these submissions and make final
recommendations, after debates with the experts and audience at the conference. This report
presents the final 37 statements and recommendations, covering assessment of candidates for liver
transplantation, criteria for listing in cirrhotic and non-cirrhotic patients, role of tumour
downstaging, management of patients on the waiting list, role of living donation, and post-
transplant management.
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Introduction
Although liver transplantation was first done in human beings by Tom Starzl in 1963, the
procedure did not begin to gain wide acceptance until the mid-1980s, when effective
immunosuppression with ciclosporin became available. Currently, overall 1-year and 5-year
survival after liver transplantation exceeds 85% and 70%, respectively, in most centres.1,2
Hepatocellular carcinoma (HCC) is a major health problem worldwide, which continues to
increase because of the association of HCC with hepatitis B and C viruses. HCC was one of
the first indications for liver transplantation, because it was postulated that this approach
would eliminate the tumour and cure the underlying liver disease. However, it soon became
apparent that the success of liver transplantation depends on the tumour load; patients with
extensive disease had very poor outcomes, whereas most patients with small tumours could
be cured. This led to many controversies around the use of liver transplantation in patients
with HCC, such as the selection of patients in the context of worldwide organ shortage,
control of the tumour load while patients wait for a graft, use of living donors, and the
choice of immunosuppression or adjuvant therapies.
The goal of liver transplantation, regardless of the underlying disease, is providing liver
recipients with the maximum benefit possible from the limited resource of deceased and
living donor organs, in a fair, ethical, and cost-effective manner. Thus, indications for the
procedure and allocation of donor organs are closely scrutinised by all stakeholders in liver
transplantation. With the endorsement of most international societies concerned with liver
transplantation or HCC, we organised a conference that aimed to reach wide consensus
throughout the medical and non-medical population on various aspects of the use of liver
transplantation for patients with HCC, based on the best available evidence.
Methods
An international consensus conference on liver transplantation for HCC was held on Dec 2–
4, 2010, in Zurich, Switzerland, under the auspices of ten international societies focused on
liver diseases or transplantation, with the aim of establishing a consensus regarding
indications for liver transplantation in patients with HCC and to provide internationally
accepted statements and guidelines for the conduct of liver transplantation programmes. For
this purpose, we developed a novel format based on the Danish model (figure).3 The
organising committee identified key topics and appointed 19 working groups composed of
four to six experts from various areas of medicine, selected on the basis of their scientific
and clinical records, to prepare reviews of the evidence and draft recommendations.
Working groups were asked to follow the Oxford classification of levels of evidence.4 The
material prepared by the various panels is available as a supplement of Liver
Transplantation.5–24 Each working group did an English language literature search of
Pubmed, Embase, and Scopus databases, and the Cochrane central register of controlled
trials. Text, keywords, and medical subject heading terms were used for titles and abstracts.
Manual cross-referencing was also used to find further relevant articles. Search terms and
dates varied according to topic (webappendix). A jury of nine members, who were selected
from various clinical and academic areas and who were not actively involved in liver
transplantation, was appointed to review and comment on the submitted papers and to
finalise and grade the final recommendations.
Around 300 participants from five continents attended the meeting in Zurich. Each of the 19
working groups, assisted by members of the jury, prepared statements associated with a
level of evidence from their review of the literature. The chair of each working group gave a
15-min presentation covering specific questions, followed by questions from the jury and the
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audience. The prepared statements could be modified in real time according to the debates
during the conference. Then, a poll of the audience was obtained through an anonymous
electronic voting system to inform the jury of the strength of consensus.
The jury met independently after the conference to produce the final recommendations,
based on the expert reports, debates, and attendee voting. The jury concluded by voting to
assign a level of evidence for each recommendation, according to the Oxford classification,
with respect to diagnosis, prognosis, or therapy. They also determined the strength of each
recommendation according to the grading of recommendations assessment, development,
and evaluation system (GRADE).25 From the initial statements and recommendations
proposed by the panels of experts, 27 were dropped or merged with other statements or
recommendations, ten were left unchanged, and another 27 were reworded. Among the
definitive 37 statements and recommendations, the level of evidence proposed by the experts
was modified in three cases by the jury after discussion with the statistician (PMMB).
The present review was prepared by a writing committee, which included the president
(AP), vice president (BL), and statistician (PMMB) of the jury, along with three members of
the organising committee (ML, GJG, P-AC). The manuscript was circulated among the
working groups for confirmation of accuracy of the data with no possibility to alter the
recommendations. The final version was approved by each member of the jury. The
recommendations are presented in table 1.
Assessment of candidates with HCC for liver transplantation
The purpose of cancer staging is to accurately predict prognosis and to link tumour stage
with specific therapeutic interventions. The ideal staging system for HCC should take into
account tumour stage, liver function, and functional status of the patient. Several staging
systems have been developed over the past three decades, although none has gained
worldwide acceptance (table 2).26–34 The Barcelona Clinic Liver Cancer (BCLC) and
Cancer of the Liver Italian Program (CLIP) staging systems have been the most popular in
Europe and the USA, and the Japan Integrated Staging Score (JIS) in Japan. The BCLC is
the only system that links prognosis with treatment recommendations, and thereby was
selected in several major trials of HCC therapy. For example, the role of portal hypertension
in selecting patients for major liver resection versus liver transplantation has been validated
in Japan35 and the USA.36
Pathological features in the explanted liver that have prognostic value for staging HCC
include tumour size and number of nodules, satellite lesions, vascular invasion (macroscopic
or microscopic), and lymph-node metastases. However, staging systems to guide therapy
before liver transplantation are necessary and are mainly based on imaging information.
Preoperative and post-transplant liver staging systems can be used in assessing outcome.
This led to recommendations 1 and 2: (1) when considering treatment options for patients
with HCC, the BCLC staging system is the preferred staging system to assess the prognosis
of patients with HCC; (2) the TNM system (7th edn), including pathological examination of
the liver, should be used for determining the prognosis after transplantation with the addition
of the assessment of microvascular invasion.
Despite incremental technological advances in cross-sectional imaging techniques
(ultrasonography, CT, and MRI), standard imaging methods can underestimate or
overestimate the extent of HCC in up to 25% of cases, compared with pathological findings
of the explanted liver.18 Recent reports suggest that either dynamic CT or MRI, including
unenhanced, arterial, portal venous, and delayed phases, provide improved sensitivity and
specificity compared with standard techniques of the past. Currently, there is no data
showing the superiority of either MRI or CT. Conclusive imaging features rely on the
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presence of arterial enhancement followed by washout on portal venous or delayed
imaging.37 Such examinations should follow established protocols, which define the amount
and rate of contrast given, the precise individualised timing of image acquisition, and image
reconstruction with minimum slice thickness. Dynamic ultrasonography has improved the
accuracy of ultra sonography, but is less useful than CT or MRI because of the inability to
reliably acquire images of the entire liver during a particular contrast phase. Bone
scintigraphy has been used for evaluating bone metastases; however, the technique is poor in
terms of cost-effectiveness when used routinely. There is insufficient data to propose 18F-
fluorodeoxyglucose (FDG)-PET for staging HCC before liver transplantation. These finding
are summarised in recommendations 3 and 4: (3) either dynamic CT or dynamic MRI with
the presence of arterial enhancement followed by washout on portal venous or delayed
imaging is the best non-invasive test to make a diagnosis in cirrhotic patients suspected of
having HCC and for preoperative staging; (4) extrahepatic staging should include CT of the
chest, and CT or MRI of the abdomen and pelvis.
Because of improvements in the accuracy of non-invasive imaging, the need for liver biopsy
in the work-up of cirrhotic patients with HCC being considered for liver transplantation has
changed in recent years. The specificity of liver biopsy is close to 100%, but sensitivity
varies depending on location of the tumour, needle size (86–90% with an 18 gauge cutting
needle, 67% with 21–22 gauge needle), and tumour size (>90% for nodules >1 cm vs 83%
for nodules <1 cm). A positive tumour biopsy is clinically relevant to rule in a diagnosis of
HCC, but a negative biopsy is less useful. There is also the risk of tumour seeding after liver
biopsy, which has been reported to be 2·7% (95% CI 1·8–4·0) with a median time interval
between biopsy and seeding of 17 months (IQR 7–48).38
The American Association for the Study of Liver Disease (AASLD) has proposed an
algorithm for diagnosis of HCC based on availability of state-of-the-art CT or MRI.39 These
data are summarised as recommendations 5 and 6: (5) tumour biopsy is not required in
cirrhotic patients considered for liver transplantation who have high-quality dynamic CT or
MRI findings typical for HCC and a lesion larger than 1 cm according to current AASLD
guidelines; (6) for patients with lesions smaller or equal to 10 mm or atypical findings, non-
invasive imaging does not allow an accurate diagnosis, and should not be used to make a
decision for or against transplantation.
Criteria for listing candidates with HCC in cirrhotic livers for deceased-
donor liver transplantation
In the context of shortage of available grafts, decisions have to take into account the
collective benefit of all potential liver recipients, in addition to the benefit for the individual
patient. Liver transplantation achieves excellent results in patients with limited tumour load.
Patients with solitary HCC of less than 5 cm or with up to three nodules of less than 3 cm
(the Milan criteria40) have a 5-year survival of 70% after liver transplantation, with
recurrence in less than 10%. This survival matches post-transplant survival of most other
indications for liver transplantation.1,2
In the context of organ shortage for liver transplantation, an extension of the boundaries of
transplantation for HCC must take into account the benefit for individual HCC patients as
well as the consequences for all potential liver recipients. Whether, and to what extent, post-
transplant survival could be lowered, because of expansion of the HCC receiver pool, while
remaining acceptable, depends on the effect on mortality for non-HCC patients awaiting
transplantation. Even though a survival opportunity considerably lower than that achieved in
non-HCC patients might be considered worth the risk of surgery for some patients with
HCC, the negative effects on others on the donor list must be taken into consideration. This
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led to recommendation 7: liver transplantation should be reserved for HCC patients who
have a predicted 5-year survival comparable to non-HCC patients.
Among criteria used for listing patients with HCC, gross features of tumours are important.
Burroughs and colleagues41 did a meta-analysis of 101 studies assessing the effect of HCC
staging in terms of size and number of nodules on post-transplant recurrence and survival.
74 of the studies, comprising 22 432 patients, were used for quantitative analysis. There was
variability in the reporting of tumour characteristics, with information missing for time on
the waiting list, immunosuppression, and bridging therapy. Two-thirds of the studies were
based on explant findings, and few compared pretransplant imaging with explant data. If
multiple versus single nodules were considered, the definition of multiple was poorly
reported. Burroughs and colleagues41 concluded that assessment of the diameter of the
largest nodule or total diameter of nodules was the best predictor of outcome, and that total
tumour size (sum of diameters) of 10 cm or larger (vs <10 cm) was associated with a four-
times increased risk of death or recurrence. Measurement of volume might be a better way
to assess tumour burden, but the data to support this are not yet available.42 A study using
the Organ Procurement and Transplant Network (OPTN) database suggested that a total
tumour volume cutoff at 115 cm3 and α-fetoprotein concentration higher than 400 ng/mL
could discriminate between patients with acceptable outcome and those with poor
outcome.43 There is insufficient evidence regarding the effect of number of nodules on
outcome of liver transplantation.
This led to recommendation 8: preoperative assessment of the size of the largest tumour or
total diameter of tumours should be the main consideration in selecting HCC patients for
liver transplantation. In 1996, after a period of unrestricted indications for liver
transplantation, associated with overall 5-year survival below 50%, the Milan criteria were
introduced. These criteria set restrictive limits for size and number of tumours in candidates
for liver transplantation.40 Mazzaferro and colleagues44 did a systematic review that
included 90 studies, comprising 17 780 patients over 15 years (1612 patients in level 1b
studies, 16 043 in level 2 studies, and 125 in level 4 studies). Their review showed that the
Milan criteria are an independent prognostic factor for outcome after liver transplantation.
Application of the Milan criteria for patients with HCC with chronic hepatitis and cirrhosis
achieves similar post-transplant survival to that in non-HCC indications. In the European
Liver Transplant Registry (ELTR), Organ Procurement and Transplantation Network
(OPTN), and Australia and New Zealand Liver Transplant Registry (ANZLTR), 5-year
survival for non-HCC was 65–87%.1,2,45 The jury concluded with recommendation 9: the
Milan criteria are currently the benchmark for selection of HCC patients for liver
transplantation, and the basis for comparison with other suggested criteria.
As evidence accumulated of good outcomes in some patients outside the Milan criteria,
there was a drive to identify expanded criteria and to increase the number of eligible
candidates for liver transplantation. Among the many proposals, only the University of
California San Francisco (UCSF) criteria (one tumour ≤6·5 cm, three nodules at most with
the largest ≤4·5 cm, and total tumour diameter ≤8 cm) have been prospectively validated by
the proponent group, with outcome data comparable to those from other retrospective
studies.46,47 This is summarised in recommendation 10: a modest expansion of the number
of potential candidates may be considered on the basis of several studies showing
comparable survival for patients outside the Milan criteria.
It is essential to consider how expansion of criteria beyond the Milan criteria might affect
the survival of candidates for liver transplantation who do not have HCC. According to
studies based on Markov models48 using data from the USA, patients outside the Milan
criteria would need to achieve 5-year survival of 60% or higher to prevent a substantial
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decrement to the life-years available to the entire population of candidates for liver
transplantation. The effect on non-HCC patients could vary widely, depending on the
composition of the population on the waiting list and the scarcity of available donor livers in
a transplant region and in individual centres. Any decision by a centre to expand criteria
should take into account the current mortality on the waiting list, and should only be done if
a low mortality will not be substantially increased by additional expanded-criteria cases. For
example, a centre with very low or no mortality on the waiting list might expand their
criteria for patients with HCC with lower post-transplant survival than that expected for non-
HCC candidates, whereas such strategy would not be acceptable in another centre with a
high death rate on the waiting list. Thus, the jury proposed recommendation 11: patients
with a worse prognosis may be considered for liver transplantation outside the Milan criteria
if the dynamics on the waiting list allow it without undue prejudice to other recipients with a
better prognosis.
Since gross features of tumours are unable to define subclasses of patients with better
biology and outcome, several biomarkers have been studied—eg, G3, EpCAM, miR26, and
poor-survival gene signatures. However, these biomarkers have not been studied in the
setting of liver transplantation.49 Several studies highlighted the value of preoperative α-
fetoprotein concentrations in predicting outcome after liver transplantation,43,50,51 but there
is no agreement on the cutoff values to consider, which ranged from 200 to 1000 ng/mL. A
recent study using the Scientific Registry of Transplant Recipients (SRTR) data suggested
adding α-fetoprotein concentration to total tumour volume as a predictor of outcome after
liver transplantation.43 In several studies, α-fetoprotein concentration lower than 400 ng/mL
has been used in selecting patients for liver transplantation after downstaging protocols, in
addition to criteria based on tumour size and number.52 Another group found that dynamic
changes in α-fetoprotein concentrations higher than 15 ng/mL are the most relevant
preoperative predictor of recurrence and overall survival after orthotopic liver
transplantation.50 Recommendations 12 and 13 summarise this topic: (12) α-fetoprotein
concentrations add prognostic information in HCC patients and may be used for making
decisions regarding transplantation in combination with imaging criteria; (13) biomarkers
other than α-fetoprotein cannot yet be used for clinical decision making regarding liver
transplantation for HCC.
HCC often involves branches of portal or hepatic veins (or both), causing a tumour
thrombus. Vascular invasion of HCC affects prognosis after liver transplantation.53–55
Macrovascular invasion involves branches of portal or hepatic veins, or both. It can be
detected using high-quality imaging and in a pathological specimen, and is generally
considered an absolute contraindication for liver transplantation. Micro vascular invasion,
which is identified only by microscopic observation, is associated with poorer outcome or
increased recurrence rates after liver transplantation. Although it correlates with larger
tumour size (>3 cm), multiple nodules, histological grade (moderately vs poor
differentiated), and gross features such as confluent multinodular type,56 microvascular
invasion cannot be reliably detected before transplantation and is therefore not useful for
clinical decision making.
Conventional imaging modalities are ineffective for preoperative detection of microvascular
invasion. Only one study suggested a value for PET in predicting microvascular invasion.57
Several studies from Japan suggested that serum concentrations of des-gamma-
carboxyprothrombin (also known as protein induced by vitamin K absence [PIVKA])
correlate well with microvascular invasion.58,59 Positive and negative correlations of α-
fetoprotein with microvascular invasion have been reported. The available data led to
recommendation 14: indication for liver trans plantation in HCC should not rely on
microvascular invasion because it cannot be reliably detected prior to transplantation.
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Criteria for HCC candidates with non-cirrhotic livers
Although most HCC occurs in patients with liver cirrhosis, about 10% of cases arise in
absence of cirrhosis. In such patients, diagnosis is often made at an advanced stage.
Resection is currently the preferred therapeutic option, when feasible, since patients with
good liver reserve have high tolerance for extensive liver resection.60 However, as in
cirrhotic patients, the risk of local recurrence is high, ranging from 30 to 73%, and affects 5-
year overall survival (25–81%) and disease-free survival (24–54%).61,62 Several
pathological features are associated with poor prognosis, such as the presence of satellite or
multiple nodules, microvascular and macrovascular invasion, and R1 resection. The subtype
of fibrolamellar HCC seems to have similar outcomes.63
Data from the ELTR suggest that liver transplantation might be appropriate in some non-
cirrhotic patients with recurrent HCC after resection, with long-term survival approaching
60% at 5 years.64 In this study, the absence of cirrhosis or fibrosis, and seronegativity for
hepatitis C and hepatitis B virus was confirmed in all patients. Macrovascular and lymph-
node invasion, and early recurrence (<1 year) after resection were significant risk factors for
poor outcome. Tumour diameter and Milan criteria of the initial HCC were unrelated to
outcome.
There are few reports of cases of primary liver transplantation in non-cirrhotic patients with
HCC.64,65 The data available suggest that the risk factors for poor outcomes after liver
transplantation are the same as those identified for recurrent disease after resection. Patients
without these risk factors had a 5-year survival of 67%, even though most had tumours
outside the Milan criteria. This information led to recommendations 15 and 16: (15) the
Milan criteria and its modifications are not applicable to patients with HCC developing in a
non-cirrhotic liver. Such patients with non-resectable HCC and absence of macrovascular
invasion and extrahepatic spread may be considered as appropriate candidates for liver
transplantation; (16) patients with HCC in a non-cirrhotic liver, who were treated by
resection and have intrahepatic recurrence of HCC and no evidence of macrovascular
invasion or extrahepatic spread, may be considered for salvage transplantation.
Role of downstaging of HCC
The goal of downstaging using locoregional therapy—eg, alcohol injection, radiofrequency
ablation (RFA), transarterial chemoembolisation (TACE), transarterial radioembolisation
(TARE), or liver resection—is to decrease the tumour size and number in patients initially
presenting with tumours that do not meet locally acceptable criteria for liver transplantation.
Success in downstaging has been reported in many studies, although most of these are
uncontrolled observational studies with no method emerging as superior and each carrying
some risk. The largest experience is with TACE and RFA.66 Two prospective studies
showed that survival after liver transplantation in patients with large tumour burden
successfully treated by downstaging was similar to survival in patients who initially met the
criteria for transplantation.52,67 These issues are addressed in recommendations 17 and 18:
(17) transplantation may be considered after successful downstaging; (18) liver
transplantation after successful downstaging should achieve a 5-year survival comparable to
that of HCC patients who meet the criteria for liver transplantation without requiring
downstaging.
There is debate about how best to assess successful downstaging. European Association for
the Study of the Liver (EASL) guidelines suggest that such assessment should be
exclusively based on the amount of viable tumour, as differentiated from necrosis by
contrast CT or MRI.68 Most available reports have used the Milan criteria to define
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successful downstaging.52,67,69 There is currently no well defined upper limit for size and
number of lesions as eligibility criteria for downstaging, although the presence of vascular
invasion and extrahepatic disease are generally considered absolute con train dications.
Some groups add serum α-fetoprotein concentrations for assessment of downstaging;
however, there is no agreement on a threshold. Recommendations 19 and 20 address
downstaging: (19) criteria for successful downstaging should include tumour size and
number of viable tumours; (20) α-fetoprotein concentrations before and after downstaging
may add additional information.
Once a tumour has been successfully downstaged to within acceptable criteria, a minimum
observation period of 3 months is often recommended before considering liver
transplantation. It is crucial to define criteria for failure of downstaging, which may include,
before listing: failure to achieve listing criteria, tumour progression with development of
vascular invasion, extrahepatic spread, or tumour size and number remaining beyond
inclusion criteria; and, after listing: tumour progression requiring delisting and recurrence of
HCC after liver transplantation. This consideration led to statement 21: based on existing
evidence, no recommendation can be made for preferring a specific locoregional therapy for
downstaging over others.
Managing patients on the waiting list
With increases in waiting times for liver transplantation in many centres, it has become
common practice to monitor patients with HCC to ensure that they remain within the
acceptability criteria for liver transplantation. Strategies have also been developed to treat
patients whose HCC is at risk or shows signs of progression while waiting for a graft. There
is no agreement about specific timing or optimum imaging methods to use for these patients,
although a 3-month interval is common.
Recommendations are based on the known capabilities of the imaging methods used for
diagnosis and staging of HCC (see recommendations 3 and 12). There are also reports
showing that a rise in α-fetoprotein concentration is associated with poorer outcome after
liver transplantation, and of reduction in that risk by successful locoregional therapy. This
information is reflected in recommendation 22: periodic waiting-list monitoring should be
performed by imaging (dynamic CT, dynamic MRI, or contrast-enhanced ultrasonography)
and serum α-fetoprotein measurements.
Dropout of HCC patients on the waiting list is common because of cancer progression or
other medical reasons. Locoregional therapy as a bridging strategy for patients on the
waiting list aims to decrease tumour-related dropout rates and reduce the incidence of
recurrent diseases after liver transplantation. Several cohort studies and a preliminary
analysis of large registries suggest that bridging strategies with locoregional therapy are
likely to be beneficial for patients having to wait 6 months or longer.70 There is, however,
no evidence that bridging strategies are of any benefit in patients with United Network for
Organ Sharing (UNOS) T1 tumours (<2 cm). Bridging strategies might be appropriate for
patients with UNOS T2 lesions (one nodule 2–5 cm or three or fewer nodules each ≤3 cm)
who are likely to wait 6 months or longer. The presence of larger tumours and high α-
fetoprotein concentrations seem to predict a higher risk for dropout.
Although the most popular bridging strategy is TACE, pathological studies show a marginal
advantage for RFA in terms of tumour necrosis.71,72 Liver resection before transplantation
in patients with well preserved liver function, and newer strategies such as a combination of
TACE with RFA and use of 90yttrium radioembolisation or targeted therapies, have shown
some benefits in preliminary studies. This topic is summarised by the following three
statements from the jury: (23) based on current absence of evidence, no recommendation
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can be made on bridging therapy in patients with UNOS T1 (≤2 cm) HCC; (24) in patients
with UNOS T2 (one nodule 2–5 cm or three or fewer nodules each ≤3 cm) HCC (Milan
criteria) and a likely waiting time of longer than 6 months, locoregional therapy may be
appropriate; (25) no recommendation can be made for preferring one type of locoregional
therapy to others. The topic also generated two additional recommendations: (26) patients
found to have progressed beyond criteria acceptable for listing for liver transplantation
should be placed on hold and considered for downstaging; (27) patients with progressive
disease, in whom locoregional therapy intervention is not considered appropriate or is
ineffective, should be removed from the waiting list.
Role of living-donor liver transplantation for HCC
Living-donor liver transplantation (LDLT) using the right or left hemiliver of a healthy
donor is the only option for liver transplantation in some countries, particularly in Asia,
where there is limited or no availability of deceased-donor organs. LDLT has also been used
in other countries with well established programmes for organ donation from brain dead or
non-heart-beating donors, because of organ shortage, long waiting times associated with
deaths on the waiting list, drop-out due to medical reasons, or progression of tumours
beyond acceptable criteria.
The main issue in LDLT is donor safety, because of the risk of complications or death, even
if small. The concept of double equipoise was proposed to describe the balance between the
recipient’s survival benefit with LDLT and the risk of a complication or death of a healthy
donor.73 The risks and benefits need to be openly discussed and understood by all parties
involved in such cases, and meet the test of equipoise.
Some studies have suggested a higher risk of tumour recurrence with the use of partial grafts
from living relatives versus whole grafts from deceased donors. Six studies compared
deceased-donor liver transplantation (DDLT) and LDLT for HCC, including a report from a
multicentre US consortium of LDLT centres.74–79 No convincing difference in outcome
could be identified according to type of graft, although a higher risk of recurrence was noted
in fast-tracked patients, since a short delay between diagnosis and liver transplantation might
not allow enough time for the biological behaviour of the tumour to manifest. Therefore, it
might be important to consider a period of observation (eg, 3 months) when offering LDLT
in recipients with HCC. This topic is covered in recommendations 28 and 29: (28) LDLT is
acceptable for HCC patients who have an expected 5-year survival similar to comparably
staged patients receiving a deceased-donor liver. In LDLT, careful attention should be given
to psychosocial considerations regarding both donor and recipient; (29) LDLT must be
restricted to centres of excellence in liver surgery and liver transplantation to minimise
donor risk and maximise recipient outcome.
Should LDLT be offered to patients with tumour stages beyond the accepted criteria for
listing for deceased donation? This might seem to be ethically acceptable, since unlike
deceased-donor donation, other listed patients are not adversely affected by this process.
However, the question raises ethical concerns regarding the double equipoise principle,
since the risk to the donor might not be acceptable below a certain expected survival
threshold for the recipient. There was considerable disagreement among the experts at the
conference on what that threshold might be. Those who set a priority on donor protection
would not consider offering LDLT to patients with a tumour beyond criteria for DDLT,
whereas others supported the procedure even for patients with a very dismal prognosis, to
maximise individual patient benefit and patients’ choice.
The jury recognised that there are differences in current practice and suggested that any
institution using LDLT should take a clear position, make it known to the public, and, when
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endorsing criteria beyond those accepted for deceased donation, provide rigorous safeguards
to guarantee full disclosure to donor and recipients and to prevent donor coercion and
increased risk-taking by the surgical team.
The use of deceased-donor organs is usually justified for graft failure after LDLT.80 The
panel of experts supported use of deceased-donor graft for failed LDLT, even if extended
criteria were used. Rates of retrans plantation because of graft failure after LDLT are
typically low, and when needed, outcomes are excellent. The jury agreed with the use of
retransplantation in recipients who received a living graft within the accepted criteria for
liver transplantation. However, based on utility, justice, and equity, they did not support
retransplantation for patients who were beyond these criteria, because these patients would
not have qualified for DDLT in the first place, and their acceptance of LDLT did not benefit
patients on the DDLT waiting list. The vote of the audience at the conference was in line
with this re com mendation (46% strongly disagreed and 25% disagreed with the use of
retransplantation in patients beyond the accepted criteria). This discussion led the jury to
formulate recommendations 30 and 31: (30) in patients following LDLT for HCC within the
accepted regional criteria for DDLT, retransplantation for graft failure is justified; (31) in
patients following LDLT for HCC outside the accepted regional criteria for DDLT,
retransplantation for graft failure using a deceased-donor organ is not recommended.
Post-transplant management
The main concern after liver transplantation for HCC is the risk of tumour recurrence, which
occurs in 8–20% of recipients.81 HCC recurrence is usually seen within the first 2 years after
liver transplantation, and is associated with a median survival of less than 1 year (IQR 7–18
months) from the time of diagnosis.82 The adoption of routine imaging and α-fetoprotein
monitoring has led to the detection of early recurrence, with a possibility of cure with
ablation therapies in up to a third of cases.83 However, studies addressing the issue of
protocols for monitoring are scarce. A limitation for the use of routine imaging examination
(CT or MRI) is the high cost or poor cost-effectiveness to detect HCC recurrence, and most
centres have limited their application to every 6 months or yearly intervals for the first 3–5
years after liver transplantation or in the presence of abnormal α-fetoprotein concentrations,
leading to recommendation 32: post-transplant monitoring may include 6–12-monthly
contrast-enhanced CT or MRI imaging and α-fetoprotein measurements.
There is debate about how to adjust the immunosuppression in HCC patients after liver
transplantation. Immunosuppressive drugs are associated with oncogenic properties in
experimental models, and most programmes are careful to balance the inherent risks of
rejection and tumour recurrence.84 However, there are no randomised controlled trials
(RCTs) that have shown that lowering immunosuppression reduces the risk of HCC
recurrence after liver transplantation.
One class of immunosuppressive drugs, the mTOR inhibitors, might be of particular
relevance for patients with HCC who receive a liver transplantation, since experimental
studies have shown that this drug has strong immunosuppressive effects with concomitant
anti-neoplastic properties.85 Uncontrolled pilot trials and retrospective analyses have
suggested that sirolimus, an mTOR inhibitor, was associated with lower tumour recurrence
and improved survival after liver transplantation;86–88 however, these results have not been
confirmed in an RCT. This topic is covered in statements 33 and 34: (33) there is currently
insufficient evidence from clinical trials to base a recommendation for choosing the type or
dose of immunosuppression therapy to influence the incidence of HCC recurrence or its
prognosis; (34) based on current evidence, no recommendation can be made on the use of
mTOR inhibitors to reduce the risk of HCC recurrence outside clinical trials.
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To assess whether adjuvant therapies are effective to decrease post-transplantation tumour
recurrence and improve overall survival, the experts identified eight uncontrolled studies
(226 patients)89–96 and four RCTs (213 patients).96–100 Difficulties in interpreting these
studies include variability in the drugs tested (doxorubicin, cisplatin, fluorouracil,
gemcitabine, or mithoxanthrone) and in the inclusion criteria and endpoints selected, and
small sample sizes. Single-arm, retrospective studies suggest a benefit for using adjuvant
therapy, but their level of evidence is too low (level 4) to support recommendations.
Controlled studies have also provided inconsistent results.
Two compounds show some early promise: sorafenib and licartin. Sorafenib, a multitargeted
tyrosine-kinase inhibitor, has been shown to have an antitumour effect in patients with
advanced HCC,101 and is currently being studied as adjuvant therapy after resection or
ablation of HCC in a multicentre phase 3 trial (STORM trial). Licartin, a 131I-radiolabelled
murine monoclonal antibody that specifically binds HCC cells, was shown to have a positive
effect on prevention of tumour recurrence and on survival, in a small, placebo-controlled,
randomised, double-blind study.97 This led to recommendation 35: current evidence does
not justify the routine use of adjuvant antitumour therapy after liver transplantation for HCC
outside of a controlled clinical trial.
There is considerable debate about how to treat HCC recurrence after liver transplantation.
Most recurrences are associated with systemic tumour dissemination, thus retransplantation
is not indicated. A distinction must be made for de-novo HCC, which typically occurs at a
later stage and most often in the setting of recurrent hepatitis C and advancing fibrosis. Such
cases should probably be treated as having new tumours and retransplantation might be
justified;102 however, the data to support this approach are limited.
Locoregional therapy for HCC recurrence, including liver resection, radiofrequency
ablation, or TACE, has been successfully used in selected patients with limited disease, and
might be considered when technically feasible.103 Sorafenib has been used with limited
side-effects after liver transplantation, sometimes in conjunction with mTOR inhibitors, and
might be considered when systemic treatment is warranted.104 This topic is summarised in
the last two recommendations: (36) HCC recurrence after liver transplantation may be
treated by surgery for resectable lesions or by locoregional therapy or systemic therapy
(including sorafenib) for unresectable lesions; (37) liver retransplantation is not appropriate
treatment for recurrent HCC.
Conclusion
The 37 recommendations and statements presented here cover the most controversial topics
surrounding liver transplantation for HCC, and may guide transplantation programmes
around the world to improve management of their HCC patients. The phrasing of many
recommendations permits adjustment according to variations in programme and regional
circumstances, among which might be team experience and the availability of donor organs
or living donation. Although the conference was not designed to address future areas of
research, the existence of weak recommendations or absence of recommendation in a
controversial area might serve as the basis to identify key questions that urgently require
convincing answers.
Acknowledgments
This consensus conference was endorsed and sponsored by the American Association for the Study of Liver
Disease (AASLD), American Society of Transplant Surgeons (ASTS), European Association for the Study of the
Liver (EASL), European-African Hepato-Pancreato-Biliary Association (E-AHPBA), European Liver and Intestine
Transplant Association (ELITA), International Hepato-Pancreato-Biliary Association (IHPBA), International Liver
Clavien et al. Page 11
Lancet Oncol. Author manuscript; available in PMC 2012 August 13.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Cancer Association (ILCA), International Liver Transplantation Society (ILTS), and The Transplantation Society
(TTS). We acknowledge the generous financial support from the industry including Bayer HealthCare, Novartis,
Astellas, Johnson & Johnson, Roche, MSD, AstraZeneca, Nycomed, B Braun, Baxter, MeVis, CAScination, and
Microsulis Medical. These companies were neither involved in the selection of topics, nor in the choice of experts
or members of the jury. The conference was also supported by a grant from the University of Zurich and the Liver
and Gastro-Intestinal Foundation. Finally, we thank Carol De Simio and Stefan Schwyter (University Hospital
Zurich) for their help in preparing the figure.
OLT for HCC consensus group
Organising committee—J Belghiti (France); J Bruix (Spain); P-A Clavien (Switzerland); G
Gores, D W Hanto, G Klintmalm, M Charlton (USA); C-M Lo (China); R J Porte
(Netherlands).
Jury—A Perrier (president; Switzerland); B Langer (vice-president; Canada); G Barritt,
(Australia); P Bossuyt (Netherlands); R Finn, B Hippen (USA); A Hisham (Malaysia); P
Marcellin (France); A Sexton Dobby (Switzerland).
Chairs of the expert panels—A K Burroughs (UK); C Duvoux, D Samuel (France); A S H
Gouw (Netherlands); D Grant, P Greig, N Kneteman (Canada); J M Lee (Korea); J Lerut
(Belgium); J Llovet (Spain); V Mazzaferro (Italy); P Majno, B Müllhaupt (Switzerland); R
Freeman, K Olthoff, E Pomfret, M Schwartz, J Trotter, F Yao (USA).
Details of members of the expert panels, local organising committee, and writing committee
can be found in the webappendix p1.
References
1. European Liver Transplant Registry. [accessed Jan 1, 2011] Results. 2011.
www.eltr.org/spip.php?rubrique37.
2. Organ Procurement and Transplantation Network. [accessed Jan 1, 2011] OPTN/SRTR Annual
Report. www.ustransplant.org/annual_reports.
3. Grundahl, J. The Danish consensus conference model. In: Joss, S.; Durant, J., editors. Public
participation in science: the role of consensus conferences in Europe. London: Science Museum;
1995.
4. Oxford Centre for Evidence-based Medicine. Levels of evidence. 2009 Mar. http://www.cebm.net/
index.aspx?o=1025.
5. Lesurtel M, Clavien PA. 2010 international consensus conference on liver transplantation for
hepatocellular carcinoma: texts of experts. Liver Transpl. 2011; 17(suppl 2):S1–S5. [PubMed:
21656651]
6. Samuel D, Colombo M, El-Serag H, Sobesky R, Heaton N. Toward optimizing the indications for
orthotopic liver transplantation in hepatocellular carcinoma. Liver Transpl. 2011; 17(suppl 2):S6–
S13. [PubMed: 21858912]
7. Müllhaupt B, Durand F, Roskams T, Dutkowski P, Heim M. Is tumor biopsy necessary? Liver
Transpl. 2011; 17(suppl 2):S14–S25. [PubMed: 21744470]
8. Olthoff KM, Forner A, Hübscher S, Fung J. What is the best staging system for hepatocellular
carcinoma in the setting of liver transplantation? Liver Transpl. 2011; 17(suppl 2):S26–S33.
[PubMed: 21656653]
9. Lee JM, Trevisani F, Vilgrain V, Wald C. Imaging diagnosis and staging of hepatocellular
carcinoma. Liver Transpl. 2011; 17(suppl 2):S34–S43. [PubMed: 21739567]
10. Mazzaferro V, Bhoori S, Sposito C, et al. Milan criteria in liver transplantation for hepatocellular
carcinoma: an evidence-based analysis of 15 years of experience. Liver Transpl. 2011; 17(suppl
2):S44–S57. [PubMed: 21695773]
Clavien et al. Page 12
Lancet Oncol. Author manuscript; available in PMC 2012 August 13.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
11. Germani G, Gurusamy K, Garcovich M, et al. Which matters most: Number of tumors, size of the
largest tumor, or total tumor volume? Liver Transpl. 2011; 17(suppl 2):S58–S66. [PubMed:
21584928]
12. Llovet JM, Paradis V, Kudo M, Zucman-Rossi J. Tissue biomarkers as predictors of outcome and
selection of transplant candidates with hepatocellular carcinoma. Liver Transpl. 2011; 17(suppl
2):S67–S71. [PubMed: 21594967]
13. Gouw AS, Balabaud C, Kusano H, Todo S, Ichida T, Kojiro M. Markers for microvascular
invasion in hepatocellular carcinoma: where do we stand? Liver Transpl. 2011; 17(suppl 2):S72–
S80. [PubMed: 21714066]
14. Prasad KR, Young RS, Burra P, et al. Summary of candidate selection and expanded criteria for
liver transplantation for hepatocellular carcinoma: a review and consensus statement. Liver
Transpl. 2011; 17(suppl 2):S81–S89. [PubMed: 21748847]
15. Lerut J, Mergental H, Kahn D, et al. Place of liver transplantation in the treatment of hepatocellular
carcinoma in the normal liver. Liver Transpl. 2011; 17(suppl 2):S90–S97. [PubMed: 21796760]
16. Majno P, Lencioni R, Mornex F, Girard N, Poon RT, Cherqui D. Is the treatment of hepatocellular
carcinoma on the waiting list necessary? Liver Transpl. 2011; 17(suppl 2):S98–S108. [PubMed:
21954097]
17. Yao FY, Breitenstein S, Broelsch CE, Dufour JF, Sherman M. Does a patient qualify for liver
transplantation after the down-staging of hepatocellular carcinoma? Liver Transpl. 2011; 17(suppl
2):S109–S116. [PubMed: 21584927]
18. Kneteman N, Livraghi T, Madoff D, de Santibañez E, Kew M. Tools for monitoring patients with
hepatocellular carcinoma on the waiting list and after liver transplantation. Liver Transpl. 2011;
17(suppl 2):S117–S127. [PubMed: 21584926]
19. Pomfret EA, Lodge JP, Villamil FG, Siegler M. Should we use living donor grafts for patients with
hepatocellular carcinoma? Ethical considerations. Liver Transpl. 2011; 17(suppl 2):S128–S132.
[PubMed: 21656657]
20. Grant D, Fisher RA, Abecassis M, McCaughan G, Wright L, Fan ST. Should the liver transplant
criteria for hepatocellular carcinoma be different for deceased donation and living donation? Liver
Transpl. 2011; 17(suppl 2):S133–S138. [PubMed: 21634006]
21. Greig PD, Geier A, D'Alessandro AM, Campbell M, Wright L. Should we perform deceased donor
liver transplantation after living donor liver transplantation has failed? Liver Transpl. 2011;
17(suppl 2):S139–S146. [PubMed: 21563294]
22. Duvoux C, Kiuchi T, Pestalozzi B, Busuttil R, Miksad R. What is the role of adjuvant therapy after
liver transplantation for hepatocellular carcinoma? Liver Transpl. 2011; 17(suppl 2):S147–S158.
[PubMed: 21714065]
23. Schlitt HJ, Mornex F, Shaked A, Trotter JF. Immunosuppression and hepatocellular carcinoma.
Liver Transpl. 2011; 17(suppl 2):S159–S161. [PubMed: 21506251]
24. Davis E, Wiesner R, Valdecasas J, Kita Y, Rossi M, Schwartz M. Treatment of recurrent
hepatocellular carcinoma after liver transplantation. Liver Transpl. 2011; 17(suppl 2):S162–S166.
[PubMed: 21688382]
25. Schunemann HJ, Oxman AD, Brozek J, et al. Grading quality of evidence and strength of
recommendations for diagnostic tests and strategies. BMJ. 2008; 336:1106–1110. [PubMed:
18483053]
26. Chevret S, Trinchet JC, Mathieu D, et al. A new prognostic classification for predicting survival in
patients with hepatocellular carcinoma. Groupe d’Etude et de Traitement du Carcinome
Hepatocellulaire. J Hepatol. 1999; 31:133–141. [PubMed: 10424293]
27. Kudo M, Chung H, Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP score):
its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging
Score (JIS score). J Gastroenterol. 2003; 38:207–215. [PubMed: 12673442]
28. Leung TW, Tang AM, Zee B, et al. Construction of the Chinese University Prognostic Index for
hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging
system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients.
Cancer. 2002; 94:1760–1769. [PubMed: 11920539]
Clavien et al. Page 13
Lancet Oncol. Author manuscript; available in PMC 2012 August 13.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
29. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging
classification. Semin Liver Dis. 1999; 19:329–338. [PubMed: 10518312]
30. Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in
relation to treatment. Study of 850 patients. Cancer. 1985; 56:918–928. [PubMed: 2990661]
31. Omagari K, Honda S, Kadokawa Y, et al. Preliminary analysis of a newly proposed prognostic
scoring system (SLiDe score) for hepatocellular carcinoma. J Gastroenterol Hepatol. 2004;
19:805–811. [PubMed: 15209629]
32. Tateishi R, Yoshida H, Shiina S, et al. Proposal of a new prognostic model for hepatocellular
carcinoma: an analysis of 403 patients. Gut. 2005; 54:419–425. [PubMed: 15710994]
33. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the
Cancer of the Liver Italian Program (CLIP) investigators. Hepatology. 1998; 28:751–755.
[PubMed: 9731568]
34. Wildi S, Pestalozzi BC, McCormack L, et al. Critical evaluation of the different staging systems
for hepatocellular carcinoma. Br J Surg. 2004; 91:400–408. [PubMed: 15048738]
35. Makuuchi M, Sano K. The surgical approach to HCC: our progress and results in Japan. Liver
Transpl. 2004; 10(suppl 1):46–52.
36. Bilimoria MM, Lauwers GY, Doherty DA, et al. Underlying liver disease, not tumor factors,
predicts long-term survival after resection of hepatocellular carcinoma. Arch Surg. 2001; 136:528–
535. [PubMed: 11343543]
37. Freeman RB, Mithoefer A, Ruthazer R, et al. Optimizing staging for hepatocellular carcinoma
before liver transplantation: a retrospective analysis of the UNOS/OPTN database. Liver Transpl.
2006; 12:1504–1511. [PubMed: 16952174]
38. Silva MA, Hegab B, Hyde C, et al. Needle track seeding following biopsy of liver lesions in the
diagnosis of hepatocellular cancer: a systematic review and meta-analysis. Gut. 2008; 57:1592–
1596. [PubMed: 18669577]
39. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005; 42:1208–1236.
[PubMed: 16250051]
40. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small
hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996; 334:693–699. [PubMed:
8594428]
41. Germani G, Gurusamy K, Garcovich M, et al. What matters: number of tumours, size of largest
tumour, or total volume of tumour? Liver Transpl. 2011 published online May 16.
42. Toso C, Trotter J, Wei A, et al. Total tumor volume predicts risk of recurrence following liver
transplantation in patients with hepatocellular carcinoma. Liver Transpl. 2008; 14:1107–1115.
[PubMed: 18668667]
43. Toso C, Asthana S, Bigam DL, et al. Reassessing selection criteria prior to liver transplantation for
hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database.
Hepatology. 2009; 49:832–838. [PubMed: 19152426]
44. Mazzaferro V, Bhoori S, Sposito C, et al. Milan Criteria in liver transplantation for HCC: an
evidence-based analysis on 15 years of experience. Liver Transpl. 2011 published online June 21.
45. [accessed Nov 1, 2010] Australia and New Zeland Liver Transplant Registry. 21st report.
http://www.anzltr.org/thisYear
46. Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion
of the tumor size limits does not adversely impact survival. Hepatology. 2001; 33:1394–1403.
[PubMed: 11391528]
47. Yao FY, Xiao L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: validation of
the UCSF-expanded criteria based on preoperative imaging. Am J Transplant. 2007; 7:2587–2596.
[PubMed: 17868066]
48. Volk ML, Vijan S, Marrero JA. A novel model measuring the harm of transplanting hepatocellular
carcinoma exceeding Milan criteria. Am J Transplant. 2008; 8:839–846. [PubMed: 18318783]
49. Villanueva A, Hoshida Y, Toffanin S, et al. New strategies in hepatocellular carcinoma: genomic
prognostic markers. Clin Cancer Res. 2010; 16:4688–4694. [PubMed: 20713493]
Clavien et al. Page 14
Lancet Oncol. Author manuscript; available in PMC 2012 August 13.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
50. Vibert E, Azoulay D, Hoti E, et al. Progression of alphafetoprotein before liver transplantation for
hepatocellular carcinoma in cirrhotic patients: a critical factor. Am J Transplant. 2010; 10:129–
137. [PubMed: 20070666]
51. Zheng SS, Xu X, Wu J, et al. Liver transplantation for hepatocellular carcinoma: Hangzhou
experiences. Transplantation. 2008; 85:1726–1732. [PubMed: 18580463]
52. Ravaioli M, Grazi GL, Piscaglia F, et al. Liver transplantation for hepatocellular carcinoma: results
of down-staging in patients initially outside the Milan selection criteria. Am J Transplant. 2008;
8:2547–2557. [PubMed: 19032223]
53. Lohe F, Angele MK, Rentsch M, et al. Multifocal manifestation does not affect vascular invasion
of hepatocellular carcinoma: implications for patient selection in liver transplantation. Clin
Transplant. 2007; 21:696–701. [PubMed: 17988261]
54. Parfitt JR, Marotta P, Alghamdi M, et al. Recurrent hepatocellular carcinoma after transplantation:
use of a pathological score on explanted livers to predict recurrence. Liver Transpl. 2007; 13:543–
551. [PubMed: 17394152]
55. Shah SA, Tan JC, McGilvray ID, et al. Does microvascular invasion affect outcomes after liver
transplantation for HCC? A histopathological analysis of 155 consecutive explants. J Gastrointest
Surg. 2007; 11:464–471. [PubMed: 17436131]
56. Liver Cancer Study Group of Japan. General rules for the clinical and pathological study of
primary liver cancer. Tokyo: Kanehara Co; 1997.
57. Kornberg A, Freesmeyer M, Barthel E, et al. 18F-FDG-uptake of hepatocellular carcinoma on PET
predicts microvascular tumor invasion in liver transplant patients. Am J Transplant. 2009; 9:592–
600. [PubMed: 19191771]
58. Fujiki M, Takada Y, Ogura Y, et al. Significance of des-gamma-carboxy prothrombin in selection
criteria for living donor liver transplantation for hepatocellular carcinoma. Am J Transplant. 2009;
9:2362–2371. [PubMed: 19656125]
59. Shirabe K, Itoh S, Yoshizumi T, et al. The predictors of microvascular invasion in candidates for
liver transplantation with hepatocellular carcinoma—with special reference to the serum levels of
des-gamma-carboxy prothrombin. J Surg Oncol. 2007; 95:235–240. [PubMed: 17323337]
60. Clavien PA, Petrowsky H, DeOliveira ML, et al. Strategies for safer liver surgery and partial liver
transplantation. N Engl J Med. 2007; 356:1545–1559. [PubMed: 17429086]
61. Chang CH, Chau GY, Lui WY, et al. Long-term results of hepatic resection for hepatocellular
carcinoma originating from the noncirrhotic liver. Arch Surg. 2004; 139:320–325. [PubMed:
15006892]
62. Lang H, Sotiropoulos GC, Domland M, et al. Liver resection for hepatocellular carcinoma in non-
cirrhotic liver without underlying viral hepatitis. Br J Surg. 2005; 92:198–202. [PubMed:
15609381]
63. Liu S, Chan KW, Wang B, et al. Fibrolamellar hepatocellular carcinoma. Am J Gastroenterol.
2009; 104:2617–2624. [PubMed: 19638962]
64. Mergental H, Porte RJ. Liver transplantation for unresectable hepatocellular carcinoma in patients
without liver cirrhosis. Transpl Int. 2010; 23:662–667. [PubMed: 20345561]
65. Houben KW, McCall JL. Liver transplantation for hepatocellular carcinoma in patients without
underlying liver disease: a systematic review. Liver Transpl Surg. 1999; 5:91–95. [PubMed:
10071346]
66. Lesurtel M, Mullhaupt B, Pestalozzi BC, et al. Transarterial chemoembolization as a bridge to liver
transplantation for hepatocellular carcinoma: an evidence-based analysis. Am J Transplant. 2006;
6:2644–2650. [PubMed: 16939518]
67. Yao FY, Kerlan RK, Hirose R, et al. Excellent outcome following down-staging of hepatocellular
carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology. 2008; 48:819–
827. [PubMed: 18688876]
68. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma.
Conclusions of the Barcelona-2000 EASL conference. J Hepatol. 2001; 35:421–430. [PubMed:
11592607]
Clavien et al. Page 15
Lancet Oncol. Author manuscript; available in PMC 2012 August 13.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
69. Lewandowski RJ, Kulik LM, Riaz A, et al. A comparative analysis of transarterial downstaging for
hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant. 2009;
9:1920–1928. [PubMed: 19552767]
70. Majno PE, Lencioni R, Mornex F, et al. Is treatment of HCC on the waiting list necessary? Liver
Transpl. 2011; 17(suppl 2):S98–S108. [PubMed: 21954097]
71. Martin AP, Goldstein RM, Dempster J, et al. Radiofrequency thermal ablation of hepatocellular
carcinoma before liver transplantation—a clinical and histological examination. Clin Transplant.
2006; 20:695–705. [PubMed: 17100718]
72. Pompili M, Mirante VG, Rondinara G, et al. Percutaneous ablation procedures in cirrhotic patients
with hepatocellular carcinoma submitted to liver transplantation: assessment of efficacy at explant
analysis and of safety for tumor recurrence. Liver Transpl. 2005; 11:1117–1126. [PubMed:
16123960]
73. Cronin DC, Millis JM. Living donor liver transplantation: the ethics and the practice. Hepatology.
2008; 47:11–13. [PubMed: 18161704]
74. Di Sandro S, Slim AO, Giacomoni A, et al. Living donor liver transplantation for hepatocellular
carcinoma: long-term results compared with deceased donor liver transplantation. Transplant Proc.
2009; 41:1283–1285. [PubMed: 19460539]
75. Fisher RA, Kulik LM, Freise CE, et al. Hepatocellular carcinoma recurrence and death following
living and deceased donor liver transplantation. Am J Transplant. 2007; 7:1601–1608. [PubMed:
17511683]
76. Hwang S, Lee SG, Joh JW, et al. Liver transplantation for adult patients with hepatocellular
carcinoma in Korea: comparison between cadaveric donor and living donor liver transplantations.
Liver Transpl. 2005; 11:1265–1272. [PubMed: 16184545]
77. Kulik L, Abecassis M. Living donor liver transplantation for hepatocellular carcinoma.
Gastroenterology. 2004; 127(suppl 1):277–282.
78. Lo CM, Fan ST, Liu CL, et al. Living donor versus deceased donor liver transplantation for early
irresectable hepatocellular carcinoma. Br J Surg. 2007; 94:78–86. [PubMed: 17016793]
79. Vakili K, Pomposelli JJ, Cheah YL, et al. Living donor liver transplantation for hepatocellular
carcinoma: increased recurrence but improved survival. Liver Transpl. 2009; 15:1861–1866.
[PubMed: 19938113]
80. Olthoff KM, Merion RM, Ghobrial RM, et al. Outcomes of 385 adult-to-adult living donor liver
transplant recipients: a report from the A2ALL Consortium. Ann Surg. 2005; 242:314–323.
[PubMed: 16135918]
81. Zimmerman MA, Ghobrial RM, Tong MJ, et al. Recurrence of hepatocellular carcinoma following
liver transplantation: a review of preoperative and postoperative prognostic indicators. Arch Surg.
2008; 143:182–188. [PubMed: 18283144]
82. Hollebecque A, Decaens T, Boleslawski E, et al. Natural history and therapeutic management of
recurrent hepatocellular carcinoma after liver transplantation. Gastroenterol Clin Biol. 2009;
33:361–369. [PubMed: 19398289]
83. Roberts JP. Tumor surveillance-what can and should be done? Screening for recurrence of
hepatocellular carcinoma after liver transplantation. Liver Transpl. 2005; 11(suppl 2):45–46.
84. Hojo M, Morimoto T, Maluccio M, et al. Cyclosporine induces cancer progression by a cell-
autonomous mechanism. Nature. 1999; 397:530–534. [PubMed: 10028970]
85. Soll C, Clavien PA. Inhibition of mammalian target of rapamycin: two goals with one shot? J
Hepatol. 2011; 54:182–183. [PubMed: 20952085]
86. Chinnakotla S, Davis GL, Vasani S, et al. Impact of sirolimus on the recurrence of hepatocellular
carcinoma after liver transplantation. Liver Transpl. 2009; 15:1834–1842. [PubMed: 19938137]
87. Toso C, Meeberg GA, Bigam DL, et al. De novo sirolimus-based immunosuppression after liver
transplantation for hepatocellular carcinoma: long-term outcomes and side effects.
Transplantation. 2007; 83:1162–1168. [PubMed: 17496530]
88. Toso C, Merani S, Bigam DL, et al. Sirolimus-based immunosuppression is associated with
increased survival after liver transplantation for hepatocellular carcinoma. Hepatology. 2010;
51:1237–1243. [PubMed: 20187107]
Clavien et al. Page 16
Lancet Oncol. Author manuscript; available in PMC 2012 August 13.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
89. Stone MJ, Klintmalm GB, Polter D, et al. Neoadjuvant chemotherapy and liver transplantation for
hepatocellular carcinoma: a pilot study in 20 patients. Gastroenterology. 1993; 104:196–202.
[PubMed: 8380393]
90. Cherqui D, Piedbois P, Pierga JY, et al. Multimodal adjuvant treatment and liver transplantation
for advanced hepatocellular carcinoma. A pilot study. Cancer. 1994; 73:2721–2726. [PubMed:
8194012]
91. Roayaie S, Frischer JS, Emre SH, et al. Long-term results with multimodal adjuvant therapy and
liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters. Ann
Surg. 2002; 235:533–539. [PubMed: 11923610]
92. Hsieh CB, Chou SJ, Shih ML, et al. Preliminary experience with gemcitabine and cisplatin
adjuvant chemotherapy after liver transplantation for hepatocellular carcinoma. Eur J Surg Oncol.
2008; 34:906–910. [PubMed: 18166289]
93. Olthoff KM, Rosove MH, Shackleton CR, et al. Adjuvant chemotherapy improves survival after
liver transplantation for hepatocellular carcinoma. Ann Surg. 1995; 221:734–741. [PubMed:
7794077]
94. Zhang ZH, Ma LW, Song SB, et al. Adjuvant chemotherapy after orthotopic liver transplantation
for advanced hepatocellular carcinoma. Zhonghua Zhong Liu Za Zhi. 2005; 27:45–47. (in
Chinese). [PubMed: 15771799]
95. Chen GH, Lu MQ, Cai CJ, et al. Clinical study of adjuvant individualized chemotherapy for
hepatocellular carcinoma after liver transplantation. Zhonghua Wai Ke Za Zhi. 2004; 42:1040–
1043. (in Chinese). [PubMed: 15498315]
96. Sun J, Hou BH, Jian ZX, et al. Value of perioperative adjuvant therapy in liver transplantation for
advanced hepatocellular carcinoma. Nan Fang Yi Ke Da Xue Xue Bao. 2007; 27:471–473. (in
Chinese). [PubMed: 17545034]
97. Xu J, Shen ZY, Chen XG, et al. A randomized controlled trial of Licartin for preventing hepatoma
recurrence after liver transplantation. Hepatology. 2007; 45:269–276. [PubMed: 17256759]
98. Soderdahl G, Backman L, Isoniemi H, et al. A prospective, randomized, multi-centre trial of
systemic adjuvant chemotherapy versus no additional treatment in liver transplantation for
hepatocellular carcinoma. Transpl Int. 2006; 19:288–294. [PubMed: 16573544]
99. Pokorny H, Gnant M, Rasoul-Rockenschaub S, et al. Does additional doxorubicin chemotherapy
improve outcome in patients with hepatocellular carcinoma treated by liver transplantation? Am J
Transplant. 2005; 5:788–794. [PubMed: 15760403]
100. Li N, Zhou J, Weng D, et al. Adjuvant adenovirus-mediated delivery of herpes simplex virus
thymidine kinase administration improves outcome of liver transplantation in patients with
advanced hepatocellular carcinoma. Clin Cancer Res. 2007; 13:5847–5854. [PubMed: 17908978]
101. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl
J Med. 2008; 359:378–390. [PubMed: 18650514]
102. Kita Y, Klintmalm G, Kobayashi S, et al. Retransplantation for de novo hepatocellular carcinoma
in a liver allograft with recurrent hepatitis B cirrhosis 14 years after primary liver transplantation.
Dig Dis Sci. 2007; 52:392–393.
103. Taketomi A, Fukuhara T, Morita K, et al. Improved results of a surgical resection for the
recurrence of hepatocellular carcinoma after living donor liver transplantation. Ann Surg Oncol.
2010; 17:2283–2289. [PubMed: 20204531]
104. Yoon DH, Ryoo BY, Ryu MH, et al. Sorafenib for recurrent hepatocellular carcinoma after liver
transplantation. Jpn J Clin Oncol. 2010; 40:768–773. [PubMed: 20494947]
Clavien et al. Page 17
Lancet Oncol. Author manuscript; available in PMC 2012 August 13.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 1. Format of the HCC consensus conference
The role of the organising committee, expert groups, and jury at each step of the conference.
HCC=hepatocellular carcinoma. GRADE=grading of recommendations assessment,
development, and evaluation.
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Table 1
Summary of recommendations and statements
Level of
evidence
Strength of
recommendation
Assessment of candidates with HCC for liver transplantation
1. When considering treatment options for patients with HCC, the BCLC staging system is the preferred
staging system to assess the prognosis of patients with HCC
2b (P) Strong
2. The TNM system (7th edn) including pathological examination of the explanted liver, should be used for
determining prognosis after transplantation with the addition of assessment of microvascular invasion
2b (P) Strong
3. Either dynamic CT or dynamic MRI with the presence of arterial enhancement followed by washout on
portal venous or delayed imaging is the best non-invasive test to make a diagnosis in cirrhotic patients
suspected of having HCC and for preoperative staging
1b (D) Strong
4. Extrahepatic staging should include CT of the chest, and CT or MRI of the abdomen and pelvis 3b (D) Strong
5. Tumour biopsy is not required in cirrhotic patients considered for liver transplantation who have high-
quality dynamic CT or MRI findings typical for HCC and a lesion larger than 1 cm according to current
AASLD guidelines
1b (D) Weak
6. For patients with lesions smaller or equal to 10 mm, non-invasive imaging does not allow an accurate
diagnosis and should not be used to make a decision for or against transplantation
1b (D) Strong
Criteria for listing candidates with HCC in cirrhotic livers for DDLT
7. Liver transplantation should be reserved for HCC patients who have a predicted 5-year survival comparable
to non-HCC patients
NA Weak
8. Preoperative assessment of the size of the largest tumour or total diameter of tumours should be the main
consideration in selecting patients with HCC for liver transplantation
2a (P) Strong`
9. The Milan criteria are currently the benchmark for the selection of HCC patients for liver transplantation,
and the basis for comparison with other suggested criteria
2a (P) Strong
10. A modest expansion of the number of potential candidates may be considered on the basis of several
studies showing comparable survival for patients outside the Milan criteria
3b (P) Weak
11. Patients with worse prognosis may be considered for liver transplantation outside the Milan criteria if the
dynamics of the waiting list allow it without undue prejudice to other recipients with a better prognosis
NA Weak
12. α-fetoprotein concentrations add prognostic information in HCC patients and may be used for making
decisions regarding transplantation in combination with imaging criteria
2b (P) Weak
13. Biomarkers other than α-fetoprotein cannot yet be used for clinical decision making regarding liver
transplantation for HCC
2b (P) Strong
14. Indication for liver transplantation in HCC should not rely on microvascular invasion because it cannot be
reliably detected prior to transplantation
2b (P) Strong
Criteria for HCC candidates with non-cirrhotic livers
15. The Milan criteria and its modifications are not applicable to patients with HCC developing in a non-
cirrhotic liver. Such patients with non-resectable HCC and absence of macrovascular invasion and
extrahepatic spread may be considered as appropriate candidates for liver transplantation
4 (P) Weak
16. Patients with HCC in non-cirrhotic liver who were treated by resection, and have intrahepatic recurrence
of HCC and no evidence of lymph node or macrovascular invasion, may be considered for salvage
transplantation
4 (P) Weak
Role of downstaging
17. Transplantation may be considered after successful downstaging 5 (P) Weak
18. Liver transplantation after successful downstaging should achieve a 5-year survival comparable to that of
HCC patients who meet the criteria for liver transplantation without requiring downstaging
5 (P) Strong
19. Criteria for successful downstaging should include tumour size and number of viable tumours 4 (P) Strong
20. α-fetoprotein concentrations before and after downstaging may add additional information 4 (P) Weak
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Level of
evidence
Strength of
recommendation
21. Based on existing evidence, no recommendation can be made for preferring a specific locoregional
therapy for downstaging over others
NA None
Managing patients on the waiting list
22. Periodic waiting-list monitoring should be performed by imaging (dynamic CT, dynamic MRI, or
contrast-enhanced ultrasonography) and α-fetoprotein measurements
5 (P) Strong
23. Based on current absence of evidence, no recommendation can be made on bridging therapy in patients
with UNOS T1 (≤2 cm) HCC
NA None
24. In patients with UNOS T2 (one nodule 2–5 cm or three or more nodules each ≤3 cm) HCC (Milan
criteria) and a likely waiting time longer than 6 months, locoregional therapy may be appropriate
4 (P) Weak
25. No recommendation can be made for preferring any type of locoregional therapy to others NA None
26. Patients found to have progressed beyond criteria acceptable for listing for liver transplantation should be
placed on hold and considered for downstaging
5 (P) Strong
27. Patients with progressive disease in whom locoregional intervention is not considered appropriate, or is
ineffective, should be removed from the waiting list
5 (P) Strong
Role of LDLT
28. LDLT is acceptable for HCC patients who have an expected 5-year survival similar to comparably staged
patients receiving a deceased donor liver. In LDLT, careful attention should be given to psychosocial
considerations regarding both donor and recipient
NA Weak
29. LDLT must be restricted to centres of excellence in liver surgery and liver transplantation to minimise
donor risk and maximise recipient outcome
NA Strong
30. In patients following LDLT for HCC within the accepted regional criteria for DDLT, retransplantation for
graft failure is justified
5 (P) Weak
31. In patients following LDLT for HCC outside the accepted regional criteria for DDLT, retransplantation
for graft failure using a deceased donor organ is not recommended
5 (P) Strong
Post-transplant management
32. Post-transplant monitoring may include 6–12 monthly contrast-enhanced CT or MRI imaging and α-
fetoprotein measurements
5 (P) Weak
33. There is currently insufficient evidence from clinical trials to base a recommendation for choosing the
type or dose of immunosuppression therapy to influence the incidence of HCC recurrence or its prognosis
NA None
34. Based on current evidence, no recommendation can be made on the use of mTOR inhibitors solely to
reduce the risk of HCC recurrence outside clinical trials
NA None
35. The current evidence does not justify the routine use of adjuvant antitumour therapy after liver
transplantation for HCC outside of a controlled clinical trial
NA Weak
36. HCC recurrence after liver transplantation may be treated by surgery for resectable lesions or by
locoregional therapy or systemic therapy (including sorafenib) for unresectable lesions
4 (P) Weak
37. Liver retransplantation is not appropriate treatment for recurrent HCC NA Strong
Level of evidence for each recommendation refers to the Oxford classification.4 HCC=hepatocellular carcinoma. BCLC=Barcelona Clinic Liver
Cancer. TNM=tumour, node, metastasis. P=prognosis. D=diagnosis. AASLD=American Association for the Study of Liver Diseases. NA=not
applicable. OLT=orthotopic liver transplantation. UNOS=United Network for Organ Sharing. LDLT=living donor liver transplantation.
DDLT=deceased donor liver transplantation.
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